|
Dynavax gets $3M in reworked asthma deal with AstraZeneca
Bizjournals.com (blog) Dynavax Technologies Corp. will receive $3 million upfront after the Berkeley drug developer and pharmaceutical giant AstraZeneca amended a deal to accelerate a trial on a experimental asthma treatment. Dynavax (NASDAQ: DVAX) will manage the early … Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma |
View full post on asthma – Google News